NO2776305T3 - - Google Patents
Info
- Publication number
- NO2776305T3 NO2776305T3 NO12790406A NO12790406A NO2776305T3 NO 2776305 T3 NO2776305 T3 NO 2776305T3 NO 12790406 A NO12790406 A NO 12790406A NO 12790406 A NO12790406 A NO 12790406A NO 2776305 T3 NO2776305 T3 NO 2776305T3
- Authority
- NO
- Norway
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Hematology (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461983152P | 2014-04-23 | 2014-04-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
NO2776305T3 true NO2776305T3 (hu) | 2018-01-27 |
Family
ID=53055121
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO12790406A NO2776305T3 (hu) | 2014-04-23 | 2012-11-06 |
Country Status (37)
Country | Link |
---|---|
US (3) | US9908927B2 (hu) |
EP (2) | EP3366699A1 (hu) |
JP (2) | JP6523331B2 (hu) |
KR (2) | KR102079919B1 (hu) |
CN (2) | CN106459221B (hu) |
AR (1) | AR100168A1 (hu) |
AU (3) | AU2015249649B2 (hu) |
BR (1) | BR112016024515B1 (hu) |
CA (2) | CA2946402C (hu) |
CL (1) | CL2016002683A1 (hu) |
CR (1) | CR20160516A (hu) |
CY (1) | CY1120281T1 (hu) |
DK (1) | DK3134430T3 (hu) |
DO (1) | DOP2016000284A (hu) |
EC (1) | ECSP16089579A (hu) |
ES (1) | ES2672368T3 (hu) |
HR (1) | HRP20180950T1 (hu) |
HU (1) | HUE038914T2 (hu) |
IL (2) | IL248244B (hu) |
LT (1) | LT3134430T (hu) |
MA (2) | MA45069A (hu) |
MX (2) | MX2016013858A (hu) |
MY (1) | MY181986A (hu) |
NO (1) | NO2776305T3 (hu) |
PE (1) | PE20170299A1 (hu) |
PH (1) | PH12016502079B1 (hu) |
PL (1) | PL3134430T3 (hu) |
PT (1) | PT3134430T (hu) |
RS (1) | RS57153B1 (hu) |
RU (1) | RU2699285C2 (hu) |
SG (3) | SG10202111785VA (hu) |
SI (1) | SI3134430T1 (hu) |
TR (1) | TR201806912T4 (hu) |
TW (2) | TWI683825B (hu) |
UA (1) | UA118286C2 (hu) |
UY (1) | UY36095A (hu) |
WO (1) | WO2015164588A1 (hu) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2745801C2 (ru) * | 2015-05-04 | 2021-04-01 | Аподжиникс Аг | Одноцепочечные белки-агонисты рецептора cd40 |
JP6959229B2 (ja) * | 2015-10-23 | 2021-11-02 | アポジェニックス アーゲー | 一本鎖gitr受容体アゴニストタンパク質 |
CA3002587A1 (en) | 2015-10-23 | 2017-04-27 | Apogenix Ag | Single-chain light receptor agonist proteins |
JP6917368B2 (ja) | 2015-10-23 | 2021-08-11 | アポジェニックス アーゲー | 一本鎖cd27受容体アゴニストタンパク質 |
WO2017102010A1 (en) * | 2015-12-17 | 2017-06-22 | Biontech Rna Pharmaceuticals Gmbh | Novel cytokine fusion proteins |
US10821160B2 (en) | 2016-03-01 | 2020-11-03 | The Board Of Trustees Of The University Of Illinois | L-asparaginase variants and fusion proteins with reduced L-glutaminase activity and enhanced stability |
WO2017161173A1 (en) * | 2016-03-16 | 2017-09-21 | Merrimack Pharmaceuticals, Inc. | Engineered trail for cancer therapy |
US10501744B2 (en) | 2016-05-04 | 2019-12-10 | Indiana University Research And Technology Corporation | Presentation of bioactive proteins |
TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Hdac抑制劑與pd-l1抑制劑之組合治療 |
TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
WO2017218540A1 (en) * | 2016-06-13 | 2017-12-21 | Merrimack Pharmaceuticals, Inc. | Methods for selecting and treating patients with a trail-based therapeutic or death receptor agonist |
EP3360898A1 (en) | 2017-02-14 | 2018-08-15 | Boehringer Ingelheim International GmbH | Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer |
AU2018313253A1 (en) | 2017-08-11 | 2020-02-27 | The Board Of Trustees Of The University Of Illinois | Truncated guinea pig L-asparaginase variants and methods of use |
WO2019178433A1 (en) * | 2018-03-15 | 2019-09-19 | Abbvie Inc. | Abbv-621 in combination with anti-cancer agents for the treatment of pancreatic cancer |
TW202003553A (zh) * | 2018-03-15 | 2020-01-16 | 美商艾伯維有限公司 | 用於治療癌症之abbv-621與抗癌劑之組合 |
US20230212260A1 (en) | 2020-05-15 | 2023-07-06 | Apogenix Ag | Multi-specific immune modulators |
EP4346885A1 (en) | 2021-05-28 | 2024-04-10 | Julius-Maximilians-Universität Würzburg | Recombinant proteinaceous binding molecules |
WO2023088876A1 (en) | 2021-11-16 | 2023-05-25 | Apogenix Ag | Multi-specific immune modulators |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001025277A1 (en) | 1999-10-07 | 2001-04-12 | Maxygen Aps | Single-chain antagonist polypeptides |
DE19963859A1 (de) | 1999-12-30 | 2001-07-12 | Apotech Res & Dev Ltd | Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen |
CA2314199A1 (en) | 2000-07-21 | 2002-01-21 | Robert Simoneau | C-chip |
WO2002046227A2 (en) | 2000-12-07 | 2002-06-13 | Eli Lilly And Company | Glp-1 fusion proteins |
US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
AU2003234274A1 (en) | 2002-04-26 | 2003-11-10 | California Institute Of Technology | D1-1 nucleic acids, polypeptides and related methods |
DE102004014983A1 (de) | 2004-03-26 | 2005-10-20 | Univ Stuttgart | Rekombinante Polypeptide der Mitglieder der TNF Ligandenfamilie und deren Verwendung |
US20060188498A1 (en) * | 2005-02-18 | 2006-08-24 | Genentech, Inc. | Methods of using death receptor agonists and EGFR inhibitors |
AU2006233927A1 (en) * | 2005-04-15 | 2006-10-19 | Rappaport Family Institute For Research In The Medical Sciences | Molecules and methods of using same for treating mcp-1/ccr2 associated diseases |
US8008443B2 (en) | 2005-04-26 | 2011-08-30 | Medimmune, Llc | Modulation of antibody effector function by hinge domain engineering |
EP1894940A1 (en) | 2006-08-28 | 2008-03-05 | Apogenix GmbH | TNF superfamily fusion proteins |
CA2860950C (en) | 2007-07-10 | 2017-08-01 | Apogenix Gmbh | Tnf superfamily collectin fusion proteins |
AU2009256250B2 (en) | 2008-06-03 | 2013-05-30 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
SI2310509T1 (sl) * | 2008-07-21 | 2015-07-31 | Apogenix Gmbh | TNFSF enoverižne molekule |
JP2012502994A (ja) * | 2008-09-22 | 2012-02-02 | アムジエン・インコーポレーテツド | 治療方法 |
US20100105620A1 (en) * | 2008-10-10 | 2010-04-29 | Anaphore, Inc. | Polypeptides that bind Trail-R1 and Trail-R2 |
ES2593049T3 (es) | 2009-01-09 | 2016-12-05 | Apogenix Ag | Proteínas de fusión que forman trímeros |
US20120100140A1 (en) * | 2009-01-23 | 2012-04-26 | Biogen Idec Ma Inc. | Stabilized fc polypeptides with reduced effector function and methods of use |
KR20120107122A (ko) | 2009-12-22 | 2012-09-28 | 노파르티스 아게 | 치료법에서 사용하기 위한 4가 cd47―항체 불변 영역 융합 단백질 |
WO2011130324A1 (en) | 2010-04-13 | 2011-10-20 | Medimmune, Llc | Fibronectin type iii domain-based multimeric scaffolds |
US9717803B2 (en) * | 2011-12-23 | 2017-08-01 | Innate Pharma | Enzymatic conjugation of polypeptides |
KR102201694B1 (ko) * | 2012-07-18 | 2021-01-12 | 아포게닉스 아게 | CD95-Fc 이소형의 혼합물을 포함하는 조성물 |
-
2012
- 2012-11-06 NO NO12790406A patent/NO2776305T3/no unknown
-
2015
- 2015-04-23 JP JP2016564068A patent/JP6523331B2/ja active Active
- 2015-04-23 CN CN201580031858.7A patent/CN106459221B/zh active Active
- 2015-04-23 KR KR1020167032819A patent/KR102079919B1/ko active IP Right Grant
- 2015-04-23 SG SG10202111785VA patent/SG10202111785VA/en unknown
- 2015-04-23 WO PCT/US2015/027270 patent/WO2015164588A1/en active Application Filing
- 2015-04-23 PT PT157210899T patent/PT3134430T/pt unknown
- 2015-04-23 TW TW104113087A patent/TWI683825B/zh active
- 2015-04-23 TW TW109106778A patent/TWI747178B/zh active
- 2015-04-23 RU RU2016145608A patent/RU2699285C2/ru active
- 2015-04-23 KR KR1020197035100A patent/KR20190135546A/ko not_active Application Discontinuation
- 2015-04-23 AU AU2015249649A patent/AU2015249649B2/en active Active
- 2015-04-23 CA CA2946402A patent/CA2946402C/en active Active
- 2015-04-23 HU HUE15721089A patent/HUE038914T2/hu unknown
- 2015-04-23 MX MX2016013858A patent/MX2016013858A/es active IP Right Grant
- 2015-04-23 PE PE2016002016A patent/PE20170299A1/es unknown
- 2015-04-23 SG SG11201608767XA patent/SG11201608767XA/en unknown
- 2015-04-23 US US14/694,358 patent/US9908927B2/en active Active
- 2015-04-23 SI SI201530223T patent/SI3134430T1/en unknown
- 2015-04-23 DK DK15721089.9T patent/DK3134430T3/en active
- 2015-04-23 EP EP18155146.6A patent/EP3366699A1/en not_active Withdrawn
- 2015-04-23 SG SG10201806465TA patent/SG10201806465TA/en unknown
- 2015-04-23 BR BR112016024515-6A patent/BR112016024515B1/pt active IP Right Grant
- 2015-04-23 MY MYPI2016703814A patent/MY181986A/en unknown
- 2015-04-23 UY UY0001036095A patent/UY36095A/es active IP Right Grant
- 2015-04-23 UA UAA201611802A patent/UA118286C2/uk unknown
- 2015-04-23 LT LTEP15721089.9T patent/LT3134430T/lt unknown
- 2015-04-23 TR TR2018/06912T patent/TR201806912T4/tr unknown
- 2015-04-23 RS RS20180450A patent/RS57153B1/sr unknown
- 2015-04-23 CR CR20160516A patent/CR20160516A/es unknown
- 2015-04-23 MA MA045069A patent/MA45069A/fr unknown
- 2015-04-23 EP EP15721089.9A patent/EP3134430B1/en active Active
- 2015-04-23 ES ES15721089.9T patent/ES2672368T3/es active Active
- 2015-04-23 MA MA039770A patent/MA39770A/fr unknown
- 2015-04-23 CN CN202010767219.XA patent/CN111718424A/zh active Pending
- 2015-04-23 PL PL15721089T patent/PL3134430T3/pl unknown
- 2015-04-23 AR ARP150101224A patent/AR100168A1/es active IP Right Grant
- 2015-04-23 CA CA3184067A patent/CA3184067A1/en active Pending
-
2016
- 2016-10-07 IL IL248244A patent/IL248244B/en active IP Right Grant
- 2016-10-19 DO DO2016000284A patent/DOP2016000284A/es unknown
- 2016-10-19 PH PH12016502079A patent/PH12016502079B1/en unknown
- 2016-10-21 CL CL2016002683A patent/CL2016002683A1/es unknown
- 2016-10-21 MX MX2019013587A patent/MX2019013587A/es unknown
- 2016-11-23 EC ECIEPI201689579A patent/ECSP16089579A/es unknown
-
2018
- 2018-02-02 US US15/887,509 patent/US20180222962A1/en not_active Abandoned
- 2018-05-25 CY CY20181100568T patent/CY1120281T1/el unknown
- 2018-06-19 HR HRP20180950TT patent/HRP20180950T1/hr unknown
- 2018-11-30 AU AU2018271369A patent/AU2018271369B2/en active Active
-
2019
- 2019-04-24 JP JP2019082671A patent/JP6714751B2/ja active Active
-
2020
- 2020-02-11 IL IL272612A patent/IL272612A/en unknown
- 2020-03-30 AU AU2020202247A patent/AU2020202247A1/en not_active Abandoned
- 2020-08-14 US US16/993,569 patent/US20210040178A1/en not_active Abandoned